-
New Study Suggests Cannabis Sativa Extracts Could Help Prevent Or Reverse Sun Damage
Tuesday, June 4, 2024 - 2:42pm | 532Read More...Funded by Thailand's Ministry of Industry and Thai-China Flavours and Fragrances Industry Co Ltd. (TCFF), the new study suggests that Cannabis sativa extracts might help prevent or treat photoaging, also known as sun damage. Photoaging occurs with prolonged overexposure to the sun, which can cause...
-
MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer
Monday, July 26, 2021 - 9:36am | 195Read More...MediWound Ltd (NASDAQ: MDWD) has initiated a Phase 1/2 study of MW005 to treat low-risk Basal Cell Carcinoma (BCC). In parallel, an investigator-initiated Phase 2 trial of MW005 in non-melanoma skin cancers is being conducted at the Soroka Medical Center in Israel. ...
-
Sanofi - Regeneron's Immunotherapy Scores European Approval For Skin And Lung Cancer Settings
Friday, June 25, 2021 - 8:51am | 247Read More...The European Commission (EC) has approved Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo (cemiplimab) for two additional indications - basal cell carcinoma (BCC) and non-small cell lung cancer with over 50% PD-L1 expression. BCC (...
-
Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer
Wednesday, February 10, 2021 - 6:24am | 244Read More...Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) immunotherapy Libtayo (cemiplimab-rwlc) has scored approval from the FDA for the treatment of advanced basal cell carcinoma (BCC), the most common type of skin cancer in the U.S. The...
-
CureVac Expands Early-Stage Study Evaluating CV8102 In Skin Cancer
Thursday, February 4, 2021 - 12:09pm | 333Read More...CureVac N.V. (NASDAQ: CVAC) has expanded its ongoing Phase 1 study with its lead RNA-based cancer drug candidate, CV8102, intending to confirm safety, tolerability, and efficacy of CV8102 in patients with advanced melanoma at 600µg, the selected dose to be...
-
Checkpoint Therapeutics CEO On Tapping Into A $25 Billion Cancer Treatment Market
Wednesday, May 20, 2020 - 8:33am | 1382Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Since its establishment in 2014 by founding company Fortress Biotech, Inc. (NASDAQ: FBIO), biopharmaceutical company Checkpoint...
-
Biofrontera Celebrates Successful IPO, Prepares For US Expansion
Friday, April 6, 2018 - 11:54am | 821Read More...Biofrontera AG ADR (NASDAQ: BFRA) is trading 53 percent above its Feb. 14 initial public offering price, justifying the company's pursuit of a U.S. market debut. The German company added a Nasdaq listing alongside a presence on the Frankfurt Stock Exchange to increase not only capital, but also...
-
Sensus Healthcare CEO On Republican Government: 'Our Product Can Survive'
Wednesday, December 21, 2016 - 2:33pm | 538Read More...Sensus Healthcare Inc (NASDAQ: SRTS) is micro-cap manufacturer of superficial radiation therapy (SRT) devices for the treatment of skin cancer and keloids, which went public on the Nasdaq exchange in June. Benzinga recently had the chance to chat with the company’s CEO Joseph C. Sardano, who...
-
Sensus Healthcare CEO On IPO, Finances And Stock Performance: 'We Are Very Comfortable'
Tuesday, December 20, 2016 - 12:29pm | 1208Read More...Sensus Healthcare Inc (NASDAQ: SRTS) (NASDAQ: SRTSW) is a micro-cap manufacturer of superficial radiation therapy (SRT) devices for the treatment of skin cancer and keloids, which went public on the Nasdaq exchange in June. Benzinga recently had the chance to chat with the company’s CEO...
-
Sensus Healthcare CEO Shares A Look Into Skin Cancer Treatment
Monday, December 19, 2016 - 4:05pm | 798Read More...Sensus Healthcare Inc (NASDAQ: SRTS) is micro-cap manufacturer of superficial radiation therapy (SRT) devices for the treatment of skin cancer and keloids, which went public on the Nasdaq exchange in June. Benzinga recently had the chance to chat with the company’s CEO Joseph C. Sardano, who...
